WNT3A and neoplasm: In this CRC mouse model, intratumoral administration of a WNT3A targeting antibody (aWNT3A) decreased tumor volume and an increased the proportion of tumor antigen-specific CTLs in the TME, which exhibited a higher expression of T-bet and IFN-γ.